Clostridioides difficile Prevalence in the United States: National Inpatient Sample, 2016 to 2018

Molly R Petersen; Sara E Cosgrove; Eili Y Klein; Xianming Zhu; Thomas C Quinn; Eshan U Patel; M Kate Grabowski; Aaron A R Tobian

doi:10.1093/ofid/ofab409

Clostridioides difficile Prevalence in the United States: National Inpatient Sample, 2016 to 2018

Open Forum Infect Dis. 2021 Jul 30;8(9):ofab409. doi: 10.1093/ofid/ofab409. eCollection 2021 Sep.

Authors

Molly R Petersen¹, Sara E Cosgrove², Eili Y Klein³, Xianming Zhu¹, Thomas C Quinn^{2

4}, Eshan U Patel^{1

5}, M Kate Grabowski^{1

5}, Aaron A R Tobian^{1

2

5}

Affiliations

¹ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
² Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
³ Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
⁵ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Abstract

Data from the National Inpatient Sample indicate that Clostridioides difficile prevalence decreased from 10.1 (95% confidence interval [CI] = 9.9-10.3) to 8.6 (95% CI = 8.5-8.8) per 1000 hospital discharges between 2016 and 2018, after accounting for age, sex, and race. There was heterogeneity in the prevalence and decrease in prevalence by geographic region in the United States.

Keywords: Clostridioides difficile; NIS; National Inpatient Sample; antimicrobial stewardship.

Grants and funding

U01 CK000589/CK/NCEZID CDC HHS/United States